I studied at the University of Melbourne, embarking on a PhD in Pharmacology studying oestrogen metabolites and models of breast tumour growth. With an interest in vivo model system, I moved to the University of Edinburgh, UK to explore immune responses and how the lung responds to infections, allergens and injury. I obtained an Asthma UK and Medical Research Fellowship and moved to the University of Manchester to develop and utilise models of allergic airway pathology to better understand immune responses and extracellular matrix remodelling. In 2022 I relocated to the University of Aberdeen with a growing interest in using spatial methods to uncover key immuno-matrix networks that drive lung disease.

Thai Tran is an Associate Professor in the Department of Physiology and Infectious Disease Translational Research Program at the National University of Singapore (NUS). She leads a dynamic research group investigating how the microenvironment (extracellular matrix including laminin and its adaptor protein, CD151) interacts with cells of the lung and how dysregulation of this interaction contributes to lung pathophysiology. Within this theme, her laboratory has two major areas of research focus: (A) Role of laminin and CD151 in lung disease pathophysiology (including asthma, influenza infection, and lung cancer) through molecular, cellular, and disease model approaches and (B) Identification of novel therapeutic targets of lung diseases. Thai is also the Education Director for the Life Sciences, Vice-President of the Singapore Pharmacological Society, NUS Medicine Faculty Academic Advisory Committee member, and Associate Professorial Faculty Promotion and Tenure Committee member. She has won awards in research (NUS Medicine Young Researcher of the Year Award 2019), teaching (NUS Medicine Faculty Teaching Excellence Award, 2016 and 2019), and graduate mentoring (NUS Medicine Graduate Mentor of the Year Award 2018).

Clive Page is an Emeritus Professor of Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease, and he has published over 300 scientific papers and book chapters. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company and was instrumental in the discovery and development of Ensifentrine for the treatment of COPD and other respiratory diseases which was recently approved by the FDA. . He is a Trustee and Chairman of the Board of Trustees of the Fraunhofer Institute of Toxicology and Experimental Medicine in Hannover. Clive is also a Non Executive Director of Ananda Developments. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both Pharmaceutical and Biotech companies. Clive has previously held Non Executive Board positions at Cardiome in Canada, Stirling Products Ltd in Perth, Australia, Immune Regulation Ltd, EpiEndo, PreP Biopharma, Babraham Biotechnology Ltd and as a Trustee of the Babraham Institute, Cambridge. Clive is a former Chairman of the Animal Science Group of the Royal Society of Biology and has contributed widely to the public debate about the use of animals in Research. Clive is a recent past President of the British Pharmacological Society. Clive was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Royal Society of Biology President’s Medal in 2012 for “Outstanding Contributions to the Life Sciences”. He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society and the Faculty of Pharmaceutical Medicine, Royal College of Physicians. Clive was awarded an OBE for “Services to Pharmacology” in 2017.